(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...
(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...
Cruise trends for 2025 include new mega ships and exclusive upmarket yachting experiences with Japan the top 'bucket list' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback